Comparison of Bevacizumab and Triamcinolone for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion in a Pair-Matched AnalysisGuthoff R.a · Meigen T.a · Hennemann K.a · Schrader W.a, b
aDepartment of Ophthalmology, University of Würzburg, Würzburg, and bMaximilians Hospital Nürnberg, Nürnberg, Germany
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background: To compare the outcome of bevacizumab or triamcinolone acetate (TA) treatment in patients with macular edema (ME) after branch retinal vein occlusion (BRVO). Methods: In a retrospective assessment, 10 bevacizumab-treated patients and 10 TA-treated with ME after BRVO were pair-matched according to initial best-corrected visual acuity (BCVA) and central macular thickness (CMT) as measured by Stratus optical coherence tomography (OCT). BCVA and CMT were the main endpoints. Results: The initial BCVA was 0.2 ± 0.13 in bevacizumab-treated patients and 0.2 ± 0.16 in TA-treated patients, with a CMT of 497 ± 102 µm and 517 ± 88 µm, respectively. Following bevacizumab, the mean final BCVA increased by 2.8 ± 4 lines, and by 0.6 ± 3.5 lines in patients receiving TA. The mean final CMT was 238 ± 118 µm and 195 ± 243 µm in the respective treatment groups. Conclusions: Both treatments decreased the CMT, but only bevacizumab induced an improvement in BCVA from baseline, which was significant 8 weeks after treatment, but no longer significant after 13 months.
© 2010 S. Karger AG, Basel
- Cugati S, Wang JJ, Rochtchina E, Mitchell P: Ten-year incidence of retinal vein occlusion in an older population: the Blue Mountains Eye Study. Arch Ophthalmol 2006;124:726–732.
- Greer DV, Constable IJ, Cooper RL: Macular oedema and retinal branch vein occlusion. Aust J Ophthalmol 1980;8:207–209.
- Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, Mishima HK: Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309–315.
- Branch Vein Occlusion Study Group: Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271–282.
- Chen SD, Lochhead J, Patel CK, Frith P: Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol 2004;88:154–155.
- Cunningham MA, Edelman JL, Kaushal S: Intravitreal steroids for macular edema: the past, the present, and the future. Surv Ophthalmol 2008;53:139–149.
- Jonas JB, Akkoyun I, Kamppeter B, Kreissig I, Degenring RF: Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65–71.
- Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M: Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol 1998;341:309–315.
- Badala F: The treatment of branch retinal vein occlusion with bevacizumab. Curr Opin Ophthalmol 2008;19:234–238.
- Jaissle GB, Szurman P, Bartz-Schmidt KU: Recommendation for the implementation of intravitreal injections: statement of the German Retina Society, the German Society of Ophthalmology (DOG) and the German Professional Association of Ophthalmologists (BVA). Klin Monatsbl Augenheilkd 2005;222:390–395.
- Shroff D, Mehta DK, Arora R, Narula R, Chauhan D: Natural history of macular status in recent-onset branch retinal vein occlusion: an optical coherence tomography study. Int Ophthalmol 2008;28:261–268.
- Fung AE, Rosenfeld PJ, Reichel E: The International Intravitreal Bevacizumab Safety Survey: using the Internet to assess drug safety worldwide. Br J Ophthalmol 2006;90:1344–1349.
- Jonas JB: Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38:218–245.
- Jaissle GB, Leitritz M, Gelisken F, Ziemssen F, Bartz-Schmidt KU, Szurman P: One-year results after intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:27–33.
- Kriechbaum K, Michels S, Prager F, Georgopoulos M, Funk M, Geitzenauer W, Schmidt-Erfurth U: Intravitreal Avastin for macular oedema secondary to retinal vein occlusion: a prospective study. Br J Ophthalmol 2008;92:518–522.
- Chung EJ, Hong YT, Lee SC, Kwon OW, Koh HJ: Prognostic factors for visual outcome after intravitreal bevacizumab for macular edema due to branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1241–1247.
- Wu L, Arevalo JF, Roca JA, Maia M, Berrocal MH, Rodriguez FJ, Evans T, Costa RA, Cardillo J: Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina 2008;28:212–219.
- Rabena MD, Pieramici DJ, Castellarin AA, Nasir MA, Avery RL: Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion. Retina 2007;27:419–425.
- Çekîç O, Chang S, Tseng JJ, Barile GR, del Priore LV, Weissman H, Schiff WM, Ober MD: Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851–855.
- Chen SD, Sundaram V, Lochhead J, Patel CK: Intravitreal triamcinolone for the treatment of ischemic macular edema associated with branch retinal vein occlusion. Am J Ophthalmol 2006;141:876–883.
- Cakir M, Dogan M, Bayraktar Z, Bayraktar S, Acar N, Altan T, Kapran Z, Yilmaz OF: Efficacy of intravitreal triamcinolone for the treatment of macular edema secondary to branch retinal vein occlusion in eyes with or without grid laser photocoagulation. Retina 2008;28:465–472.
- Riese J, Loukopoulos V, Meier C, Timmermann M, Gerding H: Combined intravitreal triamcinolone injection and laser photocoagulation in eyes with persistent macular edema after branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2008;246:1671–1676.
- Yepremyan M, Wertz FD, Tivnan T, Eversman L, Marx JL: Early treatment of cystoid macular edema secondary to branch retinal vein occlusion with intravitreal triamcinolone acetonide. Ophthalmic Surg Lasers Imaging 2005;36:30–36.
- Özkiris A, Evereklioglu C, Erkilic K, Dogan H: Intravitreal triamcinolone acetonide for treatment of persistent macular oedema in branch retinal vein occlusion. Eye 2006;20:13–17.
- Rensch F, Jonas JB, Spandau UH: Early intravitreal bevacizumab for non-ischaemic branch retinal vein occlusion. Ophthalmologica 2008;223:124–127.
Scott IU, Vanveldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M: Score Study Report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology 2009;119:504–512.
- Kreutzer TC, Alge CS, Wolf AH, Kook D, Burger J, Strauss R, Kunze C, Haritoglou C, Kampik A, Priglinger S: Intravitreal bevacizumab for the treatment of macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2008;92:351–355.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.